# Sidewinder Therapeutics funding rounds and investors

As of 14 Oct 2026, Sidewinder Therapeutics has raised $137M across 1 verified round on record; latest: $137 million Series B led by Frazier Life Sciences and Novartis, announced 8 Apr 2026.

Sidewinder Therapeutics specializes in developing bispecific antibody-drug conjugates aimed at treating difficult cancers for patients.

Website: https://sidewinderbio.com  
Headquarters: San Diego, CA  
Page: https://fireround.dev/companies/sidewinderbio.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-04-08 | Series B | $137 million | Frazier Life Sciences, Novartis | Alexandria Venture Investments, Astellas Venture Management, DCVC Bio, Goldman Sachs Alternatives, Longwood Fund, OrbiMed, Samsara BioCapital | [sidewinderbio.com](https://sidewinderbio.com/news/sidewinder-therapeutics-announces-137-million-series-b-financing-to-advance-precision-bispecific-adcs-into-clinical-development-for-cancer), [businesswire.com](https://www.businesswire.com/news/home/20260408583837/en/Sidewinder-Therapeutics-Announces-%24137-Million-Series-B-Financing-to-Advance-Precision-Bispecific-ADCs-into-Clinical-Development-for-Cancer) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.